Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SELL | P14151 | 1/20 | 0.48 |
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085354 | 0.83 | ALDH1A1 (0.44) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL28007255 | 0.83 | CYP1A2 (0.44) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL18585486 | 0.80 | SELL (0.60) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL30149140 | 0.78 | ALDH1A1 (0.57) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL565454 | 0.78 | SELL (0.64) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL317576 | 0.78 | ALDH1A1 (0.57) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL30463104 | 0.78 | SELL (0.64) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL606643 | 0.78 | SELL (0.52) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL5737114 | 0.78 | KDM4E (0.40) | GRM1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL10914869 | 0.78 | GABRP (0.44) | GRM1ALDH1A1KDM4EHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-01-07 | — | — | US | disclosed |
| EP-2953899-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | Yeda Research and Development Co., Ltd. (IL) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122664-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-14 | — | — | WO | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-4966999-A | Radiohalogenated compounds for site specific labeling | CYTOGEN CORPORATION (US) | 1990-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002269-A1 | LANTHANIDE CLUSTERS AND METHODS OF USE THEREOF | VAC14, LPXN, SLC39A7 | GRM1 3380/4885ALDH1A1 3337/4885KDM4E 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.